180 Life Sciences Corp. (ATNF)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Country | United States |
IPO Date | Jun 27, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Sir Marc Feldmann Ph.D. |
Contact Details
Address: Building 4 Palo Alto, California United States | |
Website | https://180lifesciences.com |
Stock Details
Ticker Symbol | ATNF |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001690080 |
CUSIP Number | 68236V104 |
ISIN Number | US68236V3024 |
Employer ID | 81-3832378 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Director |
Jason Assad | Director of IR |
Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder & Chairman of Clinical Advisory Board |
Sir Marc Feldmann Ph.D. | Co-Founder |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | SCHEDULE 13D | Filing |
Jan 10, 2025 | D | Filing |
Jan 03, 2025 | SCHEDULE 13G | Filing |
Jan 02, 2025 | 8-K/A | [Amend] Current Report |
Dec 31, 2024 | 8-K | Current Report |
Dec 31, 2024 | 3 | Filing |
Dec 30, 2024 | 8-K | Current Report |
Dec 30, 2024 | 424B5 | Filing |
Dec 23, 2024 | S-1/A | [Amend] Filing |
Dec 20, 2024 | S-1/A | [Amend] Filing |